No Survival Benefit When Adding Everolimus to Trastuzumab and Paclitaxel in Advanced HER2-Positive BC

Article Information

DOI 
http://dx.doi.org/10.1177/1559897715571071
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2014 SAGE Publications

Author Information

  1. Nicola Parry
  1. Sara A. Hurvitz, MD
    1. University of California at Los Angeles, Los Angeles, California, USA
View Full Text

Article usage

AbstractFullPDF
Apr 2015600
May 2015300
Jun 20151011
Jul 2015100
Aug 20151800
Sep 201510400
Oct 2015444
Nov 20154000
Total18655

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
No Survival Benefit When Adding Everolimus to Trastuzumab and Paclitaxel in Advanced HER2-Positive BC
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

combination treatment
progression-free survival
metastatic breast cancer
locally advanced breast cancer
everolimus
trastuzumab
paclitaxel
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
BOLERO-1
NCT00876395